Equal Access To Data Needed For CER To Be Effective, NPC Exec Says
Executive Summary
With the Patient-Centered Outcomes Research Institute beginning the early grant process and other data collection initiatives such as FDA’s Sentinel and Janus programs also underway, National Pharmaceutical Council Chief Science Officer Robert Dubois is recommending changes in policy that will allow equal access for industry and academia to data used in comparative effectiveness studies.
You may also be interested in...
FDA Product Promotion Regs Shouldn’t Stop Companies From Challenging CER Results, Official Says
FDA’s Bob Temple dismisses the notion that drug companies, even with FDA’s regulation of product promotions, do not have the ability to challenge comparative effectiveness research findings they believe to be false or misleading. He says FDA is in no way trying to “deny them that right.”
PCORI Funding Should Favor Areas With No Other Economic Incentives For Research, Former FDA Official Gottlieb Says
The Patient-Centered Outcomes Research Institute should focus its research agenda on areas where information is needed but is unlikely to be generated by the commercial market because there would be little financial incentive to do so, according to former government official Scott Gottlieb.
PCORI Funding Should Favor Areas With No Other Economic Incentives For Research, Former FDA Official Gottlieb Says
The Patient-Centered Outcomes Research Institute should focus its research agenda on areas where information is needed but is unlikely to be generated by the commercial market because there would be little financial incentive to do so, according to former government official Scott Gottlieb.